Form 4: FibroBiologics Chief Scientific Officer Granted Stock Options

FibroBiologics' Chief Scientific Officer, Hamid Khoja, was granted stock options for 176,200 shares on December 27, 2024.

Summary

• Hamid Khoja, the Chief Scientific Officer of FibroBiologics, Inc., was granted stock options on December 27, 2024.
• The options are for 176,200 shares of common stock at an exercise price of $2.36 per share.
• One-fourth of the options will vest on the one-year anniversary of the grant date.
• The remaining options will vest in 36 equal monthly installments after the first year, provided Mr. Khoja remains in continuous service.
• The options expire on December 26, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the interests of the Chief Scientific Officer with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the options is dependent on the future performance of FibroBiologics' stock price.
• If Mr. Khoja leaves the company before the options fully vest, he may forfeit some or all of the unvested options.

Future Outlook

The stock options will vest over time, incentivizing the Chief Scientific Officer to contribute to the company's long-term growth and success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain key talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of one-fourth after one year and the remainder over 36 months is a typical vesting structure.
• The exercise price of $2.36 is specific to FibroBiologics' stock and market conditions at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, FibroBiologics, Hamid Khoja, executive compensation, vesting, equity